- Fresenius SE 1Q Ebit before special items exceeded estimates, with EU633 million against an estimated EU617 million.
- Kabi’s Ebit before special items was EU310 million, higher than the estimated EU297.3 million.
- Vamed’s Ebit before special items was EU2 million, less than the estimated EU11.4 million.
- Helios’s Ebit before special items achieved EU353 million, beating the estimated EU326.3 million.
- Net income excluding items was EU429 million, surpassing the estimated EU405.2 million.
- Total sales were EU5.70 billion, slightly lower than the estimated EU5.73 billion.
- Kabi’s sales were EU2.05 billion, just below the estimate of EU2.08 billion.
- Vamed’s sales were EU514 million, falling short of the estimated EU556 million.
- Helios’s sales were EU3.18 billion, higher than the estimated EU3.12 billion.
- Fresenius raised its outlook for FY24 on May 7, indicating that it is now provided without Fresenius Vamed.
- Confirmation was given that the company will no longer include Vamed in reporting segments from 2Q following its exit.
- CEO Michael Sen stated that the strategic portfolio restructuring has been completed as planned with the exit from Vamed.
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Fresenius SE & Co KGaA has received positive ratings across various factors essential for long-term investment. With strong scores in Value, Dividend, and Momentum, the company is positioned well in terms of financial health, potential growth, and market performance. While Growth and Resilience scores are slightly lower, Fresenius KGaA’s overall outlook appears promising in the healthcare sector.
Fresenius SE & Co KGaA is a global healthcare group focusing on dialysis, hospital products, and medical services for patients at home. The company offers a wide range of medical equipment and pharmaceuticals, including dialysis machines, infusion systems, and diagnostic tools. With favorable ratings in key investment areas, Fresenius KGaA demonstrates strength and potential for long-term sustainability and shareholder returns.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
